Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy

Overview of attention for article published in Breast Cancer Research, April 2015

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (73rd percentile)
Above-average Attention Score compared to outputs of the same age and source (60th percentile)

Mentioned by

policy: 1 policy source
twitter: 2 tweeters

facebook: 2 Facebook pages

Citations

dimensions_citation: 27 Dimensions

Readers on

mendeley: 73 Mendeley

Summary Policy documents Twitter Facebook Dimensions citations

So far, Altmetric has seen 1 policy document that references this research output.

Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer : Appraisal consultation 1 committee papers

Cited by National Institute for Health and Care Excellence on 08 Jun 2018

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.